Software - Application
Build Your Comparison
Side-by-side financial analysisStock Comparison
CYN vs LIDR vs RBOT vs IROQ vs ZVIA vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Auto - Parts
Medical - Devices
Banks - Regional
Beverages - Non-Alcoholic
Banks - Diversified
CYN vs LIDR vs RBOT vs IROQ vs ZVIA vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||||
|---|---|---|---|---|---|---|
| Industry | Software - Application | Auto - Parts | Medical - Devices | Banks - Regional | Beverages - Non-Alcoholic | Banks - Diversified |
| Market Cap | $14M | $74M | $3M | $89M | $100M | $896.00B |
| Revenue (TTM) | $276K | $270K | $0.00 | $48M | $169M | $280.33B |
| Net Income (TTM) | $-26M | $-34M | $-42M | $5M | $-7M | $57.05B |
| Gross Margin | 34.4% | -144.1% | — | 59.5% | 47.1% | 60.0% |
| Operating Margin | -99.2% | -125.8% | — | 14.9% | -3.3% | 25.9% |
| Forward P/E | — | — | — | 19.4x | — | 14.4x |
| Total Debt | $7M | $235K | $8M | $73M | $668K | $942.38B |
| Cash & Equiv. | $990K | $43M | $3M | $20M | $25M | $343.34B |
CYN vs LIDR vs RBOT vs IROQ vs ZVIA vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Oct 21 | Jun 26 | Return |
|---|---|---|---|
| Cyngn Inc. (CYN) | 100 | 0.0 | -100.0% |
| AEye, Inc. (LIDR) | 100 | 1.0 | -99.0% |
| Vicarious Surgical … (RBOT) | 100 | 0.1 | -99.9% |
| IF Bancorp, Inc. (IROQ) | 100 | 123.2 | +23.2% |
| Zevia PBC (ZVIA) | 100 | 13.2 | -86.8% |
| JPMorgan Chase & Co. (JPM) | 100 | 188.8 | +88.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CYN vs LIDR vs RBOT vs IROQ vs ZVIA vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 6 stocks, CYN doesn't own a clear edge in any measured category.
LIDR is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 15.3%, EPS growth 79.9%, 3Y rev CAGR -60.0%
- +86.2% vs RBOT's -94.1%
RBOT ranks third and is worth considering specifically for growth.
- 31.5% revenue growth vs CYN's -40.5%
IROQ is the clearest fit if your priority is bank quality.
- NIM 2.3% vs JPM's 2.2%
ZVIA is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.92, Low D/E 1.9%, current ratio 2.08x
- Beta 0.92 vs LIDR's 2.51
JPM carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 15 yrs, beta 0.94, yield 1.9%
- 465.8% 10Y total return vs IROQ's 60.1%
- Beta 0.94, yield 1.9%, current ratio 0.52x
- Better valuation composite
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 31.5% revenue growth vs CYN's -40.5% | |
| Value | Better valuation composite | |
| Quality / Margins | 20.4% margin vs LIDR's -127.0% | |
| Stability / Safety | Beta 0.92 vs LIDR's 2.51 | |
| Dividends | 1.9% yield, 15-year raise streak, vs IROQ's 1.5%, (4 stocks pay no dividend) | |
| Momentum (1Y) | +86.2% vs RBOT's -94.1% | |
| Efficiency (ROA) | 1.3% ROA vs RBOT's -164.5%, ROIC 4.5% vs -116.2% |
CYN vs LIDR vs RBOT vs IROQ vs ZVIA vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
CYN vs LIDR vs RBOT vs IROQ vs ZVIA vs JPM — Financial Metrics
Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 4 of 6 categories
CYN leads 0 • LIDR leads 0 • RBOT leads 0 • IROQ leads 0 • ZVIA leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM and RBOT operate at a comparable scale, with $280.3B and $0 in trailing revenue. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to LIDR's -127.0%. On growth, CYN holds the edge at +121.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| RevenueTrailing 12 months | $276,397 | $270,000 | $0 | $48M | $169M | $280.3B |
| EBITDAEarnings before interest/tax | -$26M | -$34M | -$41M | $7M | -$5M | $81.4B |
| Net IncomeAfter-tax profit | -$26M | -$34M | -$42M | $5M | -$7M | $57.0B |
| Free Cash FlowCash after capex | -$27M | -$29M | -$40M | $6M | -$703,000 | $100.9B |
| Gross MarginGross profit ÷ Revenue | +34.4% | -144.1% | — | +59.5% | +47.1% | +60.0% |
| Operating MarginEBIT ÷ Revenue | -99.2% | -125.8% | — | +14.9% | -3.3% | +25.9% |
| Net MarginNet income ÷ Revenue | -94.2% | -127.0% | — | +10.8% | -4.1% | +20.4% |
| FCF MarginFCF ÷ Revenue | -97.1% | -106.7% | — | +12.4% | -0.4% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +121.8% | +57.8% | — | — | +21.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +91.1% | -63.6% | +58.1% | +115.0% | +62.5% | +16.0% |
Valuation Metrics
Evenly matched — ZVIA and JPM each lead in 2 of 5 comparable metrics.
Valuation Metrics
At 16.0x trailing earnings, JPM trades at a 17% valuation discount to IROQ's 19.4x P/E. On an enterprise value basis, JPM's 18.4x EV/EBITDA is more attractive than IROQ's 21.7x.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Market CapShares × price | $14M | $74M | $3M | $89M | $100M | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $19M | $31M | $9M | $142M | $75M | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | -0.24x | -1.78x | -0.06x | 19.38x | -9.87x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — | 0.90x |
| EV / EBITDAEnterprise value multiple | — | — | — | 21.69x | — | 18.36x |
| Price / SalesMarket cap ÷ Revenue | 62.34x | 318.04x | — | 1.84x | 0.62x | 3.20x |
| Price / BookPrice ÷ Book value/share | 0.15x | 0.74x | 0.31x | 1.02x | 2.74x | 2.47x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 13.65x | — | 8.88x |
Profitability & Efficiency
JPM leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-3 for RBOT. LIDR carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), IROQ scores 7/9 vs RBOT's 1/9, reflecting strong financial health.
| Metric | ||||||
|---|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -59.6% | -56.2% | -3.3% | +6.2% | -19.6% | +15.9% |
| ROA (TTM)Return on assets | -48.1% | -48.5% | -164.5% | +0.6% | -11.5% | +1.3% |
| ROICReturn on invested capital | -117.2% | -100.7% | -116.2% | +2.9% | -58.9% | +4.5% |
| ROCEReturn on capital employed | -71.5% | -64.7% | -134.6% | +3.9% | -24.3% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 1 | 7 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.18x | 0.00x | 0.79x | 0.89x | 0.02x | 2.60x |
| Net DebtTotal debt minus cash | $6M | -$43M | $5M | $53M | -$25M | $599.0B |
| Cash & Equiv.Liquid assets | $990,023 | $43M | $3M | $20M | $25M | $343.3B |
| Total DebtShort + long-term debt | $7M | $235,000 | $8M | $73M | $668,000 | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | -59.79x | -80.57x | — | 2.72x | — | 0.74x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $0 for CYN. Over the past 12 months, LIDR leads with a +86.2% total return vs RBOT's -94.1%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs CYN's -95.5% — a key indicator of consistent wealth creation.
| Metric | ||||||
|---|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -54.9% | -24.2% | -79.8% | -1.6% | -26.4% | -0.5% |
| 1-Year ReturnPast 12 months | -72.6% | +86.2% | -94.1% | +11.1% | -48.6% | +21.8% |
| 3-Year ReturnCumulative with dividends | -100.0% | -70.4% | -99.2% | +99.9% | -68.3% | +138.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | -99.5% | -99.8% | +25.4% | -89.2% | +118.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | -99.5% | -99.8% | +60.1% | -89.2% | +465.8% |
| CAGR (3Y)Annualised 3-year return | -95.5% | -33.4% | -80.0% | +26.0% | -31.8% | +33.6% |
Risk & Volatility
Evenly matched — IROQ and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
IROQ is the less volatile stock with a -0.05 beta — it tends to amplify market swings less than LIDR's 2.51 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs CYN's 3.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.18x | 2.51x | 2.42x | -0.05x | 0.92x | 0.94x |
| 52-Week HighHighest price in past year | $41.54 | $6.44 | $13.75 | $29.00 | $3.66 | $337.25 |
| 52-Week LowLowest price in past year | $1.22 | $0.71 | $0.35 | $23.21 | $1.11 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +3.0% | +24.8% | +3.7% | +91.6% | +40.4% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 36.0 | 36.7 | 36.5 | 34.4 | 47.6 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 277K | 3.4M | 14K | 103K | 761K | 7.0M |
Analyst Outlook
JPM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: LIDR as "Hold", ZVIA as "Buy", JPM as "Buy". Consensus price targets imply 650.0% upside for LIDR (target: $12) vs 5.9% for JPM (target: $340). For income investors, JPM offers the higher dividend yield at 1.86% vs IROQ's 1.54%.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | — | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | $12.00 | — | — | $3.50 | $339.75 |
| # AnalystsCovering analysts | — | 4 | — | — | 8 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +1.5% | — | +1.9% |
| Dividend StreakConsecutive years of raises | 2 | — | — | 0 | 1 | 15 |
| Dividend / ShareAnnual DPS | — | — | — | $0.41 | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +3.9% |
JPM leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
CYN vs LIDR vs RBOT vs IROQ vs ZVIA vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CYN or LIDR or RBOT or IROQ or ZVIA or JPM a better buy right now?
For growth investors, AEye, Inc.
(LIDR) is the stronger pick with 15. 3% revenue growth year-over-year, versus -40. 5% for Cyngn Inc. (CYN). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Zevia PBC (ZVIA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CYN or LIDR or RBOT or IROQ or ZVIA or JPM?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 0x versus IF Bancorp, Inc. at 19. 4x.
03Which is the better long-term investment — CYN or LIDR or RBOT or IROQ or ZVIA or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -100. 0% for Cyngn Inc. (CYN). Over 10 years, the gap is even starker: JPM returned +465. 8% versus CYN's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CYN or LIDR or RBOT or IROQ or ZVIA or JPM?
By beta (market sensitivity over 5 years), IF Bancorp, Inc.
(IROQ) is the lower-risk stock at -0. 05β versus AEye, Inc. 's 2. 51β — meaning LIDR is approximately -4752% more volatile than IROQ relative to the S&P 500. On balance sheet safety, AEye, Inc. (LIDR) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — CYN or LIDR or RBOT or IROQ or ZVIA or JPM?
By revenue growth (latest reported year), AEye, Inc.
(LIDR) is pulling ahead at 15. 3% versus -40. 5% for Cyngn Inc. (CYN). On earnings-per-share growth, the picture is similar: IF Bancorp, Inc. grew EPS 140. 4% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Over a 3-year CAGR, ZVIA leads at -0. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CYN or LIDR or RBOT or IROQ or ZVIA or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -145. 7% for AEye, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -136. 2% for LIDR. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CYN or LIDR or RBOT or IROQ or ZVIA or JPM more undervalued right now?
Analyst consensus price targets imply the most upside for LIDR: 650.
0% to $12. 00.
08Which pays a better dividend — CYN or LIDR or RBOT or IROQ or ZVIA or JPM?
In this comparison, JPM (1.
9% yield), IROQ (1. 5% yield) pay a dividend. CYN, LIDR, RBOT, ZVIA do not pay a meaningful dividend and should not be held primarily for income.
09Is CYN or LIDR or RBOT or IROQ or ZVIA or JPM better for a retirement portfolio?
For long-horizon retirement investors, IF Bancorp, Inc.
(IROQ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 05), 1. 5% yield). Cyngn Inc. (CYN) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IROQ: +60. 1%, CYN: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CYN and LIDR and RBOT and IROQ and ZVIA and JPM?
These companies operate in different sectors (CYN (Technology) and LIDR (Consumer Cyclical) and RBOT (Healthcare) and IROQ (Financial Services) and ZVIA (Consumer Defensive) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CYN is a small-cap quality compounder stock; LIDR is a small-cap high-growth stock; RBOT is a small-cap quality compounder stock; IROQ is a small-cap quality compounder stock; ZVIA is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. IROQ, JPM pay a dividend while CYN, LIDR, RBOT, ZVIA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.